SciClone Pharmaceuticals, Inc.

270 articles with SciClone Pharmaceuticals, Inc.

• SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange

  3/3/2021

  SciClone Pharmaceuticals Limited was officially listed on the Main Board of The Stock Exchange of Hong Kong Limited under stock code: 6600.

• EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China

  7/1/2020

  EpicentRx Inc. ("EpicentRx"), a San Diego -based clinical cancer immunotherapy company and  SciClone Pharmaceuticals International Ltd. , ("SciClone") today announced that they have enter

• Consortium Led By GL Capital Completes Acquisition Of SciClone

  10/16/2017

  SciClone and a consortium consisting of entities affiliated with GL Capital, BOCGI, CDH Investments, Ascendent Capital Partners and Boying today announced completion of the merger contemplated by the previously announced agreement and plan of merger, dated June 7, 2017.

• SciClone Announces End Of Go-Shop Period With No Parties Designated As Excluded Parties

  8/11/2017

• SciClone Reports Second Quarter 2017 Financial Results

  8/10/2017

• SciClone Accepts $605 Million Offer From China Investment Consortium

  6/8/2017

• SciClone Reports First Quarter 2017 Financial Results

  5/11/2017

• SciClone To Report First Quarter 2017 Financial Results On May 10, 2017

  5/4/2017

• SciClone Reports 2016 Financial Results And 2017 Outlook

  3/6/2017

• SciClone To Report Fourth Quarter And Full Year 2016 Financial Results On March 6, 2017

  2/21/2017

• SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG Management

  11/15/2016

• SciClone Reports Third Quarter 2016 Financial Results

  11/10/2016

• SciClone To Report Third Quarter 2016 Financial Results On November 9, 2016

  10/25/2016

• SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market

  9/26/2016

• Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

  9/12/2016

• SciClone To Present At Two Investor Conferences In September 2016

  9/2/2016

• SciClone Reports Second Quarter 2016 Financial Results

  8/10/2016

• SciClone To Report Second Quarter 2016 Financial Results On August 9, 2016

  7/28/2016

• Bay Area's SciClone Abandons Sale Strategy

  7/19/2016

• Ability Pharmaceuticals Enters Into A Licensing Agreement With SciClone Pharmaceuticals, Inc. For The Novel Anticancer Agent ABTL0812 For The China Market

  5/11/2016